

MAB- INTAKE REFERRAL (External)

Phone 401-235-6878 Fax 401-735-1060

Basic Demographic Information

Patient Name _____ DOB _____

Age _____ Preferred Language _____

Referral from: _____

Phone # _____

Referring Providers Address

Is the patient ambulatory? Yes No

Has provider reviewed FDA EUA with patient (Bamlanivimab)? Yes No

Covid-19 Related Information

Date of symptom onset _____ Date of positive test for SARS-CoV2) _____

Is the patient on home oxygen at baseline? Yes No

- If Yes, what is the patient baseline oxygen requirement _____ L/min
- What is the patient's current oxygen requirement? _____ None (room air) _____ L/min

Weight _____ Height _____ BMI _____

Pregnant? Yes No

Allergies _____

Did receive current Medication List and Past Medical History? Yes No

AUTHORIZED USE

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product bamlanivimab for the treatment of mild to moderate coronavirus disease 2019 (COVID- 19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Please check if patient has history of any of the following (circle all that apply):

☐ Age ≥ 65 years

☐ Age ≥ 55 years AND have at least one of the following conditions:

- Cardiovascular disease
- Hypertension
- Chronic obstructive pulmonary disease/other chronic respiratory disease
- Body mass index (BMI) ≥ 35
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or receiving immunosuppressive therapies

☐ 18-54 years AND have at least one of the following conditions:

- BMI ≥ 35
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or receiving immunosuppressive therapies

☐ 12 – 17 years of age AND have

- BMI ≥ 85 th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR sickle cell disease, OR
- congenital or acquired heart disease, OR
- neurodevelopmental disorders, for example, cerebral palsy, OR
- a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.